MYC gene rearrangement rate in diffuse large B-cell lymphoma is about 10%, and R-CHOP treatment has poor efficacy for DLBCL patients with MYC gene rearrangement [42]. Here, DDIT3 is linked to diffuse large B-cell lymphoma.